TP53 and myelodysplastic syndrome: TP53 mutations may initiate malignant transformation in lower-risk MDS, induce the more aggressive growth of clones, or provide survival advantages for mutated cells, such as increased proliferation or reduced apoptosis in more advanced stages of MDS.